Presumed neuroprotective therapies prescribed by veterinary ophthalmologists for canine degenerative retinal and optic nerve diseases

2021 ◽  
Author(s):  
Ryan G. Hopper ◽  
Fabiano Montiani‐Ferreira ◽  
Jorge Silva Pereira ◽  
Michele C. Fritz ◽  
Vickie J. Ruggiero ◽  
...  
Keyword(s):  
Optic Nerve ◽  
Optic Nerve Diseases ◽  
Neuroprotective Therapies

Nanomedicine for the treatment of retinal and optic nerve diseases

2013 ◽  
Vol 13 (1) ◽  
pp. 134-148 ◽  
Author(s):  
Marco Attilio Zarbin ◽  
Carlo Montemagno ◽  
James Francis Leary ◽  
Robert Ritch
Keyword(s):  
Optic Nerve ◽  
Optic Nerve Diseases

scholarly journals Cell Replacement Therapy for Retinal and Optic Nerve Diseases: Cell Sources, Clinical Trials and Challenges

Pharmaceutics ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 865
Author(s):  
Rosa M. Coco-Martin ◽  
Salvador Pastor-Idoate ◽  
Jose Carlos Pastor
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Optic Nerve ◽  
Progenitor Cells ◽  
Pluripotent Stem Cells ◽  
Limbal Stem Cells ◽  
Term Survival ◽  
Cell Therapies ◽  
Optic Nerve Diseases ◽  
Cell Sources

The aim of this review was to provide an update on the potential of cell therapies to restore or replace damaged and/or lost cells in retinal degenerative and optic nerve diseases, describing the available cell sources and the challenges involved in such treatments when these techniques are applied in real clinical practice. Sources include human fetal retinal stem cells, allogenic cadaveric human cells, adult hippocampal neural stem cells, human CNS stem cells, ciliary pigmented epithelial cells, limbal stem cells, retinal progenitor cells (RPCs), human pluripotent stem cells (PSCs) (including both human embryonic stem cells (ESCs) and human induced pluripotent stem cells (iPSCs)) and mesenchymal stem cells (MSCs). Of these, RPCs, PSCs and MSCs have already entered early-stage clinical trials since they can all differentiate into RPE, photoreceptors or ganglion cells, and have demonstrated safety, while showing some indicators of efficacy. Stem/progenitor cell therapies for retinal diseases still have some drawbacks, such as the inhibition of proliferation and/or differentiation in vitro (with the exception of RPE) and the limited long-term survival and functioning of grafts in vivo. Some other issues remain to be solved concerning the clinical translation of cell-based therapy, including (1) the ability to enrich for specific retinal subtypes; (2) cell survival; (3) cell delivery, which may need to incorporate a scaffold to induce correct cell polarization, which increases the size of the retinotomy in surgery and, therefore, the chance of severe complications; (4) the need to induce a localized retinal detachment to perform the subretinal placement of the transplanted cell; (5) the evaluation of the risk of tumor formation caused by the undifferentiated stem cells and prolific progenitor cells. Despite these challenges, stem/progenitor cells represent the most promising strategy for retinal and optic nerve disease treatment in the near future, and therapeutics assisted by gene techniques, neuroprotective compounds and artificial devices can be applied to fulfil clinical needs.

PVER Amplitude Check-Size Function Curve in Macular and Optic Nerve Diseases

1994 ◽  
Vol 34 (3) ◽  
pp. 305-309
Author(s):  
Mehul C. Mehta ◽  
Osamu Katsumi ◽  
Ryohei Wajima ◽  
Tatsuo Hirose
Keyword(s):  
Optic Nerve ◽  
Check Size ◽  
Optic Nerve Diseases ◽  
Size Function

Comparison of different classifier algorithms for diagnosing macular and optic nerve diseases

2009 ◽  
Vol 26 (1) ◽  
pp. 22-34 ◽  
Author(s):  
Kemal Polat ◽  
Sadιk Kara ◽  
Ayşegül Güven ◽  
Salih Güneş
Keyword(s):  
Optic Nerve ◽  
Optic Nerve Diseases ◽  
Classifier Algorithms
Sign in / Sign up

Export Citation Format

Share Document